Comparison of vein valve function following pharmacomechanical thrombolysis versus simple catheter-directed thrombolysis for iliofemoral deep vein thrombosis  by Vogel, David et al.
From the American Venous Forum
Comparison of vein valve function following
pharmacomechanical thrombolysis versus
simple catheter-directed thrombolysis for
iliofemoral deep vein thrombosis
David Vogel, MD,a M. Eileen Walsh, PhD,a John T. Chen, PhD,b and
Anthony J. Comerota, MD,a,c Toledo and Bowling Green, Ohio; and Ann Arbor, Mich
Background: Successful catheter-directed thrombolysis (CDT) for iliofemoral deep vein thrombosis (IFDVT) reduces
post-thrombotic morbidity and is a suggested treatment option by the American College of Chest Physicians for patients
with IFDVT. Pharmacomechanical thrombolysis (PMT) is also suggested to shorten treatment time and reduce the dose
of plasminogen activator. However, concern remains that mechanical devices might damage vein valves. The purpose of
this study is to examine whether PMT adversely affects venous valve function compared to CDT alone in IFDVT patients
treated with catheter-based techniques.
Methods: Sixty-nine limbs in 54 patients (39 unilateral, 15 bilateral) who underwent catheter-based treatment for IFDVT
form the basis of this study. Lytic success and degree of residual obstruction were analyzed by reviewing postprocedural
phlebograms. All patients underwent bilateral postprocedure duplex to evaluate patency and valve function. Phlebograms
and venous duplex examinations were interpreted in a blinded fashion. Limbs were analyzed based on the method of
treatment: CDT alone (n  20), PMT using rheolytic thrombolysis (n  14), and isolated pharmacomechanical
thrombolysis (n  35). The validated outcome measures were compared between the treatment groups.
Results: Sixty-nine limbs underwent CDT with or without PMT. The average patient age was 47 years (range, 16-78).
Venous duplex was performed 44.4 months (mean) post-treatment. Of the limbs treated with CDT with drip technique,
65% demonstrated reflux vs 53% treated with PMT (P  .42). There was no difference in long-term valve function
between patients treated with rheolytic and isolated pharmacomechanical thrombolysis. In the bilateral group, 87%
(13/15) demonstrated reflux in at least one limb. In the unilateral group, 64% (25/39) had reflux in their treated limb
and 36% (14/39) in their contralateral limb. There was no correlation effect of residual venous obstruction on valve
function, although few patients had >50% residual obstruction.
Conclusions: In patients undergoing catheter-based intervention for IFDVT, PMT does not adversely affect valve function
compared with CDT alone. A higher than expected number of patients had reflux in their uninvolved limb. (J Vasc Surg
2012;56:1351-4.)
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iIliofemoral deep venous thrombosis (IFDVT) is asso-
ciated with the most severe post-thrombotic morbidity,
reflected by reduction in quality of life, 15% of patients
developing venous ulcers within 5 years, and 40% having
venous claudication.1-3 Comerota et al4 recently demon-
strated that successful thrombus removal with the use of
catheter-based techniques is not only safe but also reduces
post-thrombotic syndrome (PTS), and others have shown
that the addition of pharmacomechanical thrombolysis
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http://dx.doi.org/10.1016/j.jvs.2012.02.053PMT) to a strategy of catheter-directed thrombolysis
CDT) improves overall lysis, shortens treatment time,
educes the dose of recombinant tissue plasminogen acti-
ator (rt-PA), and reduces intensive care unit and hospital
tay.5-7 The 2008 American College of Chest Physicians
ACCP) practice guidelines recommended a strategy of
hrombus removal for patients with extensive deep vein
hrombosis (DVT) and suggested the use of PMT to
horten the treatment time of CDT.8 However, concern
emains that PMT may harm venous valve function com-
ared with CDT drip infusion. The purpose of this study is
o evaluate the effect of PMT techniques on venous valve
unction compared with standard CDT drip technique for
he management of patients with extensive DVT.
ETHODS
Patients. Fifty-four consecutive patients with symp-
omatic acute IFDVT were treated between September
002 and November 2009 with catheter-based techniques
sing rt-PA. Fifteen patients had bilateral IFDVT, resulting
n 69 lower extremities treated, which form the basis of this
etrospective study. The study was approved by the institu-
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November 20121352 Vogel et altional review board. DVT was diagnosed on duplex ultra-
sonography and confirmed with phlebography at the time
of thrombolysis.
Twenty limbs were treated with CDT alone when only
CDT was available. Forty-nine underwent PMT. Within
the PMT group, 14 limbs were treated with the AngioJet
catheter (MEDRAD Interventional, Warrendale, Pa) and
35 limbs were treated with the Trellis catheter (Covidien,
Mansfield, Mass) when these technologies became avail-
able. The method of PMT chosen was at the discretion of
the treating interventionalist. The mean age of the patient
population was 48 years (range, 16-78). Forty-six percent
were male and 54% female. Twenty-four patients had left
lower extremity involvement, 15 had right lower extremity
involvement, and 15 were bilateral.
Residual obstruction calculation. Mewissen et al de-
scribed a method to determine the degree of clot lysis
following CDT.9 This was modified by Martinez et al5 to
further estimate the degree of successful thrombolysis.
Although this method quantifies the degree of thromboly-
sis of the acute thrombus, it does not quantify residual
obstruction from a persistent luminal stenosis. Serial phle-
bography was obtained to monitor resolution of thrombus
during treatment. The final post-thrombolysis phlebogram
was used tomeasure degree of residual luminal obstruction,
which was calculated by measuring the luminal diameter in
the area of maximal residual stenosis in the iliofemoral
segment. To best obtain an estimated normal luminal di-
ameter at the segment with residual stenosis, the normal-
appearing venous segment above and below this segment
was measured and averaged. This average was then used as
the denominator to calculate residual venous obstruction.
All patients with typical left common iliac vein stenosis due
to right iliac artery compression (May-Thurner syndrome)
had correction with venoplasty and stenting.
Venous valve function measurement. Patients who
were not treated by the authors were contacted and re-
turned to have the necessary follow-up noninvasive studies.
The majority of patients had noninvasive venous evalua-
tions performed as a routine part of follow-up care, which
averaged 44 months, with a median of 41 months. Venous
valve function was determined using venous duplex ultra-
sonography, with venous valve closure times used as the
end point.10,11 Patients were placed in a steep reverse
Trendelenburg position. Valve closure times in the com-
mon femoral, femoral, and popliteal vein segments were
measured following manual compression. Deep venous
reflux was defined as a valve closure time 1 second.11
Statistical analysis. The Student t-test was used to
assess differences in valve function and residual iliofemoral
obstruction between all treatment groups. The R-square
between valve function and residual iliofemoral obstruction
is based on a linear trend for a 10% range of residual
iliofemoral obstruction vs the mean number of limbs with
reflux in the corresponding range. R-square was also used
to compare valve function between the CDT and PMT
treatment groups. bESULTS
Residual obstruction. Only 20% of limbs had 50%
esidual obstruction in the iliofemoral venous segment on
ompletion phlebogram, and of these, 75% had obstruction
ithin the common femoral segment or external iliac vein
ust above the inguinal ligament. In limbs treated with
DT alone, 25% had50% residual luminal obstruction vs
8% of limbs treated with PMT.
Valve function. Fifty-seven percent of treated limbs
ad reflux in the common femoral, femoral, or popliteal
enous segment as measured on post-treatment duplex
ltrasound. In the group of patients with bilateral DVT,
7% (13/15) demonstrated reflux in at least one limb, 53%
8/15) had reflux in both limbs, and 13% (2/15) had no
eflux.
In the unilateral patient group, 12 of the 39 patients
31%) had valvular reflux in their treated limb only, one
3%) in the contralateral limb only, and 13 (33%) had reflux
n both of their limbs. Thirteen patients (33%) demon-
trated no reflux in either limb (Fig 1). None of the patients
ith unilateral IFDVT had a history of contralateral DVT.
Limbs treated with CDT alone had a reflux rate of 65%
s 53% in those treated with PMT (P .42) (Fig 2). Those
reated with the Trellis catheter had a reflux rate of 57%,
hereas limbs treated with the AngioJet demonstrated a
eflux rate of 43%. Further analysis between treatment
roups is illustrated in Fig 3.
Of the patients with 50% residual obstruction and
nilateral IFDVT, 70% (7/10) had reflux of their treated
imb compared to 45% (13/29) reflux with 50% residual
bstruction (P  .056).
ISCUSSION
Following acute DVT, post-thrombotic morbidity in
atients treated with anticoagulation alone is reported to
ccur in 25% to 46% of patients at 10 years.12,13 These
umbers are derived from all patients with acute DVT, not
ust those with IFDVT. Patients with IFDVT have a higher
isk for developing PTS and suffer the most severe
TS.1,2,14 The iliofemoral segment represents the single
utflow channel for the entire lower limb, and acute throm-
ig 1. Detailed analysis of valve function in legs of patients with
nilateral deep vein thrombosis (DVT).otic occlusion results in severe venous hypertension.15
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Volume 56, Number 5 Vogel et al 1353Several authors have shown that thrombus removal re-
duces PTS16-20 and improves quality of life.21 We have
previously demonstrated that PMT techniques improved
overall thrombolysis, decreased treatment times, and
reduced the dose of plasminogen activator5 and that
quality of life following CDT correlated with lytic suc-
cess.22
Despite the favorable short-term observations of PMT,
concern remains that the intraluminal mechanical manipu-
lations would adversely affect venous valve function. Our
results demonstrate that venous valve function is not im-
paired by the use of PMT techniques. There appeared to be
a tendency toward better valve function with PMT, al-
though our numbers are too small to demonstrate signifi-
cance. It was interesting to find that a relatively large
number of limbs demonstrated reflux at a mean follow-up
of 44.4 months (range, 15-99).
Prior studies have reported a wide variation in the
occurrence of deep venous reflux after the use of CDT,
ranging as low as 4% at 24 months and as high as 54% at 3
years.23,24 Van Haarst et al25 demonstrated that venous
valve function deteriorated over time following an episode
of DVT when patients were treated with anticoagulation
alone, even though the vein segments had recanalized.
They found that 48% had reflux at 34 months, which
increased to 60% at 86 months. Progressive valve dysfunc-
tion is likely due to valve entrapment by residual thrombus,
Fig 2. Valve function stratified by catheter-directed thrombolysis
(CDT) vs pharmacomechanical thrombolysis (PMT).
Fig 3. Valve function stratified by specific catheter-based tech-
nique. CDT, Catheter-directed thrombolysis.which then results in fibrosis as part of the post-thromboticesolution of the clot. This is suggested by the classic work
f Sevitt et al.26 If the thrombus is completely removed and
he valve functions normally, it is reasonable to expect the
alve to retain normal function long-term.
Interestingly, if we look at the patients in our series who
ad unilateral IFDVT and good lytic success (50% resid-
al obstruction), we found that 13 of the 29 (45%) had
eflux. However, of these, 10 had reflux in the contralateral
naffected limb; thus, it can be argued that these patients
ad pre-existing reflux in the limb with IFDVT. In patients
ith good lytic success and normal contralateral valve func-
ion, 58% (11/19) demonstrated normal valve function in
heir treated limb. In the 10 patients who had poor lytic
uccess (50% residual obstruction), 70% (7/10) had re-
ux in the treated limb and 40% had reflux in their con-
ralateral limb. This small sample size mitigates statistical
ignificance; however, it appears that successful lysis in-
reases the likelihood of preserving venous valve function.
n interesting observation was the much higher than an-
icipated number of patients with reflux in the contralateral
imb.
Limitations of this study include its small sample size
nd its retrospective design. However, its strengths are that
t is a continuous patient cohort and both the duplex
xamination and phlebograms were interpreted blinded of
ach other. All patients had both limbs studied.
In conclusion, strategies of catheter-based thrombus
emoval for IFDVT improve patient outcomes. Mechanical
lot manipulation improves speed, efficacy, and possibly
afety of CDT. The early advantages of PMT are not
ompromised by adverse effects on vein valve function.
ew observations made here raise the possibility that valve
ysfunction existed in some patients prior to their DVT.
his observation also raises an interesting hypothesis that
eep venous reflux may increase the risk for venous throm-
osis in addition to being the consequence of DVT. These
bservations warrant further investigation.
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